Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

enGene Therapeutics Inc.

NASDAQ: ENGN · Life Sciences · 2 alerts · CIK 1980845

Share price
$1.89Close, Nov 16
Market cap
$127M
Shares outstanding
67.02MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All enGene Therapeutics Inc. filings on SEC EDGAR ↗

6:15 AM ET 8-K
Clinical Trial Data

enGene Therapeutics Clinical Trial Data

enGene Therapeutics announced results from the pivotal Cohort 1 of its Phase 2 LEGEND trial evaluating detalimogene in BCG-unresponsive non-muscle invasive bladder cancer. The company also reached alignment with the FDA on key components for its planned Biologics License Application (BLA) submission.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.